Skip to main content
SpringerLink
Log in

Cancer dependencies

Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

Many precision cancer therapies function by inhibiting oncogenic signaling pathways. A new study describes the counterintuitive finding that forced hyperactivation of the same pathways can also enable selective tumor targeting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Schematic depicting the relationship between oncogenic pathway activity and cellular fitness.

References

  1. Chang, L. et al. Nat. Genet. https://doi.org/10.1038/s41588-023-01515-7 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chang, L., Ruiz, P., Ito, T. & Sellers, W. R. Cancer Cell 39, 466–479 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Konieczkowski, D. J., Johannessen, C. M. & Garraway, L. A. Cancer Cell 33, 801–815 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Courtois-Cox, S., Jones, S. L. & Cichowski, K. Oncogene 27, 2801–2809 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Das Thakur, M. et al. Nature 494, 251–255 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ito, T. et al. Nat. Genet. 53, 1664–1672 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Seong, B. K. A. et al. Cancer Cell 39, 1262–1278.e7 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ahn, E. H. Anticancer Res. 33, 2029–2035 (2013).

    CAS  PubMed  Google Scholar 

  9. The Cancer Genome Atlas. Nature 487, 330–337 (2012).

    Article  Google Scholar 

  10. Christie, M. et al. Oncogene 32, 4675–4682 (2013).

    Article  CAS  PubMed  Google Scholar 

  11. Ranes, M., Zaleska, M., Sakalas, S., Knight, R. & Guettler, S. Mol. Cell. 81, 3246–3261.e11 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schneikert, J., Grohmann, A. & Behrens, J. Hum. Mol. Genet. 16, 199–209 (2007).

    Article  CAS  PubMed  Google Scholar 

  13. Kong, X. et al. Nature 550, 270–274 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hong, A. et al. Cancer Discov. 8, 74–93 (2018).

    Article  CAS  PubMed  Google Scholar 

  15. Anforth, R., Fernandez-Penas, P. & Long, G. V. Lancet Oncol. 14, e11 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA

    Kris C. Wood

Authors
  1. Kris C. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kris C. Wood.

Ethics declarations

Competing interests

The author declares no competing financial interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wood, K.C. Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy. Nat Genet 55, 1613–1614 (2023). https://doi.org/10.1038/s41588-023-01493-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-023-01493-w

  • Springer Nature America, Inc.

Search

Navigation